<DOC>
	<DOCNO>NCT02597335</DOCNO>
	<brief_summary>This trial develop non invasive diagnostic approach IDH1 mutate gliomas combine mutation detection free plasmatic DNA , D-2HG dosage urine sample , D-2HG detection Brain Spectro MRI . In group 1 ( 25 patient ) , patient presume grade II-III glioma candidate surgery undergo spectro MRI , plasma , urine dosage . Results confront tumor mutational status D-2HG . In group 2 ( 15 patient ) , patient know IDH1 mutation undergo spectro MRI , plasma , urine dosage overtime order correlate result response treatment .</brief_summary>
	<brief_title>Non Invasive Detection IDH1/2 Mutation Gliomas</brief_title>
	<detailed_description>The aim trial develop validate non invasive diagnostic approach IDH1 mutate glioma . It evaluate specificity sensitivity D-2HG detection Brain Spectro MRI . This approach couple mutation detection free plasmatic DNA D-2HG dosage urine sample . The primary end-point quantification D-2HG spectro-MRI , correlation dosage D-2HG tumor fragment , mutational status ( group 1 : 25 patient ) . The secondary endpoint include : 1. longitudinal analysis Spectro-MRI overtime ( 12 month ) correlation radiological evolution response treatment ( group 2 : 15 patient ) 2 . Differentiation tumor recurrence radiation induce change 3 . Confrontation Spectro-MRI , D-2HG dosages IDH mutation detection plasma DNA , elaboration combine score prediction</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<criteria>Inclusion criterion 1 . Affiliation social security system 2 . Patientâ‰¥ 18 year old 3 . Written inform consent 4 . One two situation : presume grade IIIII glioma candidate surgery ( group 1 ) IDH1/IDH2 mutate grade IIIII glioma , candidate chemotherapy radiotherapy treatment , simple followup ( group 2 ) 5 . Evaluable tumoral mass min diameter &gt; 2 cm ( FLAIR ) 6 . PKPS &gt; 60 Exclusion criterion 1 . Contraindication MRI 2 . Patient unable give write Informed Consent 3 . Patient guardianship deprive freedom 4 . For group 2 : patient already include group 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Glioma</keyword>
	<keyword>IDH1/IDH2 mutation</keyword>
	<keyword>Spectroscopy MRI</keyword>
	<keyword>D-2-hydroxyglutarate</keyword>
	<keyword>Free circulating DNA</keyword>
</DOC>